BR112021007362A2 - inibidores da replicação do vírus da imunodeficiência humana - Google Patents

inibidores da replicação do vírus da imunodeficiência humana Download PDF

Info

Publication number
BR112021007362A2
BR112021007362A2 BR112021007362-0A BR112021007362A BR112021007362A2 BR 112021007362 A2 BR112021007362 A2 BR 112021007362A2 BR 112021007362 A BR112021007362 A BR 112021007362A BR 112021007362 A2 BR112021007362 A2 BR 112021007362A2
Authority
BR
Brazil
Prior art keywords
chloro
compound
indazol
ethyl
chs
Prior art date
Application number
BR112021007362-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Eric P. Gillis
Kyle E. Parcella
Manoj Patel
Kevin M. Peese
Original Assignee
VIIV Healthcare UK (No.5) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68344933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112021007362(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by VIIV Healthcare UK (No.5) Limited filed Critical VIIV Healthcare UK (No.5) Limited
Publication of BR112021007362A2 publication Critical patent/BR112021007362A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112021007362-0A 2018-10-24 2019-10-22 inibidores da replicação do vírus da imunodeficiência humana BR112021007362A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749818P 2018-10-24 2018-10-24
US62/749,818 2018-10-24
PCT/IB2019/059020 WO2020084492A1 (en) 2018-10-24 2019-10-22 Inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
BR112021007362A2 true BR112021007362A2 (pt) 2021-07-20

Family

ID=68344933

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021007362-0A BR112021007362A2 (pt) 2018-10-24 2019-10-22 inibidores da replicação do vírus da imunodeficiência humana

Country Status (25)

Country Link
US (2) US11541055B2 (https=)
EP (1) EP3870577B1 (https=)
JP (1) JP7398448B2 (https=)
KR (1) KR20210084508A (https=)
CN (1) CN113195475A (https=)
AR (1) AR116798A1 (https=)
AU (1) AU2019364739B2 (https=)
BR (1) BR112021007362A2 (https=)
CA (1) CA3117289A1 (https=)
CL (1) CL2021001025A1 (https=)
CO (1) CO2021004679A2 (https=)
CR (1) CR20210207A (https=)
DO (1) DOP2021000062A (https=)
EA (1) EA202190854A1 (https=)
ES (1) ES3026145T3 (https=)
IL (1) IL282240B2 (https=)
MA (1) MA53973A (https=)
MX (1) MX2021004593A (https=)
PE (1) PE20211781A1 (https=)
PH (1) PH12021550813A1 (https=)
PL (1) PL3870577T3 (https=)
PT (1) PT3870577T (https=)
SG (1) SG11202103560YA (https=)
TW (1) TWI824041B (https=)
WO (1) WO2020084492A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
MX2021004593A (es) * 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
LT3986561T (lt) * 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TWI902729B (zh) 2019-11-28 2025-11-01 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗hiv藥為特徵之hiv感染症的預防及治療用醫藥
UY38982A (es) 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
CN115397424A (zh) * 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
US20240423985A1 (en) * 2021-10-13 2024-12-26 Viiv Healthcare Uk (No.5) Limit-Ed Inhibitors of human immunodeficiency virus replication
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
CN121909019A (zh) 2023-09-27 2026-04-21 Viiv保健英国第三有限公司 药物组合物
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
JP2012201642A (ja) * 2011-03-25 2012-10-22 Tsutomu Takeuchi 1−フェニルピロリジン−2,5−ジオン誘導体を有効成分とするbaffの結合阻害剤
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
CA2896244C (en) 2013-01-09 2017-07-04 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
KR20170045308A (ko) * 2014-08-27 2017-04-26 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 이미다조[1,2-a]피리딘 유도체
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
KR20230011471A (ko) 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
WO2019161280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
JP7386230B2 (ja) 2018-08-09 2023-11-24 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
WO2020053811A1 (en) 2018-09-14 2020-03-19 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7433303B2 (ja) 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
FR3086760A1 (fr) 2018-10-02 2020-04-03 Institut Mines Telecom Procede d'evaluation de la resistance mecanique d'un echantillon de tissu biologique
MX2021004593A (es) * 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
US20210395262A1 (en) 2018-10-24 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210393633A1 (en) 2018-10-25 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3873607B1 (en) 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
WO2020095177A1 (en) 2018-11-05 2020-05-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210379071A1 (en) 2018-11-05 2021-12-09 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
US11429555B2 (en) 2019-02-26 2022-08-30 Apple Inc. Coprocessors with bypass optimization, variable grid architecture, and fused vector operations
AU2019356037B2 (en) 2019-04-11 2021-09-30 Goli Nutrition Inc. Apple cider vinegar nutritional supplement
EP3962603A1 (en) 2019-04-30 2022-03-09 ViiV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
LT3986561T (lt) 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai
US20220389007A1 (en) 2019-10-01 2022-12-08 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
ES2974657T3 (es) 2019-10-01 2024-07-01 Viiv Healthcare Uk No 5 Ltd Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
TW202128648A (zh) 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
JP2023517312A (ja) 2020-03-06 2023-04-25 ビーブ、ヘルスケア、ユーケー、(ナンバー5)、リミテッド ヒト免疫不全ウイルスの複製阻害剤

Also Published As

Publication number Publication date
IL282240B2 (en) 2025-05-01
CO2021004679A2 (es) 2021-04-30
CN113195475A (zh) 2021-07-30
JP2022505841A (ja) 2022-01-14
PT3870577T (pt) 2025-04-07
US20200360384A1 (en) 2020-11-19
AR116798A1 (es) 2021-06-16
PE20211781A1 (es) 2021-09-08
PL3870577T3 (pl) 2025-06-16
MX2021004593A (es) 2021-06-15
CA3117289A1 (en) 2020-04-30
US11541055B2 (en) 2023-01-03
US20230109662A1 (en) 2023-04-06
PH12021550813A1 (en) 2021-10-04
ES3026145T3 (en) 2025-06-10
IL282240A (en) 2021-05-31
DOP2021000062A (es) 2021-09-15
KR20210084508A (ko) 2021-07-07
AU2019364739A1 (en) 2021-05-20
CR20210207A (es) 2021-09-02
TWI824041B (zh) 2023-12-01
JP7398448B2 (ja) 2023-12-14
EP3870577A1 (en) 2021-09-01
SG11202103560YA (en) 2021-05-28
EA202190854A1 (ru) 2021-08-17
MA53973A (fr) 2022-02-09
CL2021001025A1 (es) 2021-11-05
AU2019364739B2 (en) 2022-05-26
TW202031261A (zh) 2020-09-01
WO2020084492A1 (en) 2020-04-30
IL282240B1 (en) 2025-01-01
EP3870577B1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
BR112021007362A2 (pt) inibidores da replicação do vírus da imunodeficiência humana
JP6861307B2 (ja) タンパク質調節因子として有用な複素環式アミド
CN108055842B (zh) 亚磺酰基苯基或磺亚胺酰基苯基苯并氮杂䓬
CN107148417B (zh) 苯并氮杂*磺酰胺化合物
US20240374598A1 (en) Inhibitors of human immunodeficiency virus replication
TW201906834A (zh) 人類免疫不全病毒複製之抑制劑
JP2022551254A (ja) ヒト免疫不全ウイルスの複製阻害剤
US20210403465A1 (en) Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
EP4041729B1 (en) Inhibitors of human immunodeficiency virus replication
TW200812979A (en) Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
RU2812128C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA043730B1 (ru) Ингибиторы репликации вируса иммунодефицита человека
HK40060467B (en) Inhibitors of human immunodeficiency virus replication
HK40060467A (en) Inhibitors of human immunodeficiency virus replication
US20250066323A1 (en) Inhibitors of human respiratory syncytial virus and metapneumovirus
HK1243701B (zh) 苯并氮杂䓬磺酰胺化合物
HK1255303B (en) Sulfinylphenyl or sulfonimidoylphenyl benzazepines
HK1255303A1 (en) Sulfinylphenyl or sulfonimidoylphenyl benzazepines
HK1231060A1 (en) Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
TW201433567A (zh) 吲唑衍生物

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]